Otonomy Inc. buy melinda
Start price
30.08.17
/
50%
€3.49
Target price
13.11.17
€6.31
Performance (%)
33.23%
End price
13.11.17
€4.65
Summary
This prediction ended on 13.11.17 with a price of €4.65. With a performance of 33.23% the BUY prediction by melinda was a big success. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Otonomy Inc. | - | - | - | - |
iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by melinda for this prediction
In the thread Otonomy Inc. diskutieren
Hersteller von Arzneimitteln
30. August (Reuters) - US - Arzneimittelhersteller Otonomy Inc. sagte am Mittwoch , dass seine Droge Meniere-Krankheit, eine chronische Erkrankung des Innenohrs zu behandeln, das Hauptziel in einer späten Studie fehlt.
(Vom Mitglied beendet)